Allison O. Dumitriu Carcoana , Jenna C. Marek , William J. West III , Cole R. Fiedler , William N. Doyle Jr. , Kristie M. Labib , Lauren C. Ladehoff , Jose A. Malavet , Gregory Fishberger , Carla C. Moodie , Joseph R. Garrett , Jenna R. Tew , Jobelle J.A.R. Baldonado , Jacques P. Fontaine , Eric M. Toloza
{"title":"机器人辅助肺叶切除术后到癌症中心的居住距离和预后","authors":"Allison O. Dumitriu Carcoana , Jenna C. Marek , William J. West III , Cole R. Fiedler , William N. Doyle Jr. , Kristie M. Labib , Lauren C. Ladehoff , Jose A. Malavet , Gregory Fishberger , Carla C. Moodie , Joseph R. Garrett , Jenna R. Tew , Jobelle J.A.R. Baldonado , Jacques P. Fontaine , Eric M. Toloza","doi":"10.1016/j.sipas.2023.100210","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Outcomes of lung cancer patients traveling greater distances for surgical oncology care are not well-described. We investigated the effects of increased travel burden after robotic-assisted pulmonary lobectomy (RAPL) for lung cancer.</p></div><div><h3>Methods</h3><p>Clinical characteristics and surgical outcomes of 711 consecutive patients who underwent RAPL from September 2010 to March 2022 were compared, stratified by primary residential ZIP code <160 km or ≥160 km from the cancer center.</p></div><div><h3>Results</h3><p>Of 711 study patients, 515 (72.4%) lived within 160 km and 196 (27.6%) lived ≥160 km away. There were no differences in Charlson Comorbidity Index scores or tumor characteristics. Those traveling ≥160 km experienced more unfavorable perioperative outcomes and postoperative complications, and had worse median survival time by 1.68 years, but this survival difference did not reach statistical significance.</p></div><div><h3>Conclusions</h3><p>With the growing centralization of cancer care, travel burden may emerge as a predictor of surgical oncology outcomes.</p></div>","PeriodicalId":74890,"journal":{"name":"Surgery in practice and science","volume":"15 ","pages":"Article 100210"},"PeriodicalIF":0.6000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Residential Distance to the Cancer Center and Outcomes after Robotic-Assisted Pulmonary Lobectomy\",\"authors\":\"Allison O. Dumitriu Carcoana , Jenna C. Marek , William J. West III , Cole R. Fiedler , William N. Doyle Jr. , Kristie M. Labib , Lauren C. Ladehoff , Jose A. Malavet , Gregory Fishberger , Carla C. Moodie , Joseph R. Garrett , Jenna R. Tew , Jobelle J.A.R. Baldonado , Jacques P. Fontaine , Eric M. Toloza\",\"doi\":\"10.1016/j.sipas.2023.100210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Outcomes of lung cancer patients traveling greater distances for surgical oncology care are not well-described. We investigated the effects of increased travel burden after robotic-assisted pulmonary lobectomy (RAPL) for lung cancer.</p></div><div><h3>Methods</h3><p>Clinical characteristics and surgical outcomes of 711 consecutive patients who underwent RAPL from September 2010 to March 2022 were compared, stratified by primary residential ZIP code <160 km or ≥160 km from the cancer center.</p></div><div><h3>Results</h3><p>Of 711 study patients, 515 (72.4%) lived within 160 km and 196 (27.6%) lived ≥160 km away. There were no differences in Charlson Comorbidity Index scores or tumor characteristics. Those traveling ≥160 km experienced more unfavorable perioperative outcomes and postoperative complications, and had worse median survival time by 1.68 years, but this survival difference did not reach statistical significance.</p></div><div><h3>Conclusions</h3><p>With the growing centralization of cancer care, travel burden may emerge as a predictor of surgical oncology outcomes.</p></div>\",\"PeriodicalId\":74890,\"journal\":{\"name\":\"Surgery in practice and science\",\"volume\":\"15 \",\"pages\":\"Article 100210\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgery in practice and science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666262023000566\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery in practice and science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666262023000566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Residential Distance to the Cancer Center and Outcomes after Robotic-Assisted Pulmonary Lobectomy
Background
Outcomes of lung cancer patients traveling greater distances for surgical oncology care are not well-described. We investigated the effects of increased travel burden after robotic-assisted pulmonary lobectomy (RAPL) for lung cancer.
Methods
Clinical characteristics and surgical outcomes of 711 consecutive patients who underwent RAPL from September 2010 to March 2022 were compared, stratified by primary residential ZIP code <160 km or ≥160 km from the cancer center.
Results
Of 711 study patients, 515 (72.4%) lived within 160 km and 196 (27.6%) lived ≥160 km away. There were no differences in Charlson Comorbidity Index scores or tumor characteristics. Those traveling ≥160 km experienced more unfavorable perioperative outcomes and postoperative complications, and had worse median survival time by 1.68 years, but this survival difference did not reach statistical significance.
Conclusions
With the growing centralization of cancer care, travel burden may emerge as a predictor of surgical oncology outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
